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Percutaneous Sclerotherapy of Renal
Cysts with a Beta-Emitting Radionuclide,
Holmium-166-chitosan Complex
Objective: To evaluate the usefulness of a beta-emitting radionuclide (holmi-
um-166-chitosan complex) as a sclerosing agent for the treatment of renal cysts.
Materials and Methods: Using 10 30 mCi of holmium-166-chitosan complex,
20 renal cysts in 17 patients (14 male and 3 female patients, ranging in age from
47 to 82 years) were treated by percutaneous sclerotherapy under ultrasono-
graphic guidance. The volume of the cysts before and after the sclerotherapy and
the percentage change in volume were calculated in order to evaluate the
response to therapy, which was classified as either complete regression (invisi-
ble), nearly complete regression (< 15 volume% of initial volume), partial regres-
sion (15 50 volume%) or no regression (> 50 volume%).
Results: The follow-up period ranged from 6 to 36 months (mean 28 months).
Eighteen cysts (90%) regressed completely (n=11, 55%) or near-completely
(n=7, 35%). Partial regression was obtained in one patient (5%) and there was
no regression in one patient (5%). No significant complications were encoun-
tered.
Conclusion: The holmium-166-chitosan complex seems to be useful as a new
painless sclerosing agent for the treatment of renal cysts with no significant com-
plications.
enal cysts are very common abnormalities, particularly in the aging adult
population. The incidence of cysts in the population over the 6th decade
is as much as 50%, and the cyst size also increases with age (1 3). In the
majority of cases, the cysts remain asymptomatic and usually require no invasive
treatment. Occasionally, however, some cysts may cause pain, hematuria or a non-
specific gastrointestinal manifestation such as nausea. There are rare incidences where
renal cysts induce infection, hypertension, obstruction of the proximal urinary tract
and even renal failure in some complicated cases (4 8).
Simple aspiration and sclerotherapy are minimally invasive procedures, and ethanol
therapy had been widely used for the treatment of symptomatic renal cysts (9 11).
The ideal sclerosing agent should be safe, painless during the procedure, have no
significant side effects and minimize recurrence. However, various ethanol-related
complications have been noted such as pain, fever and systemic reactions such as
drunken state or shock; moreover, the recurrence rate has been reported to be 32%
after a single-session alcohol sclerotherapy (11).
To overcome the drawbacks associated with the use of alcohol as a sclerosing agent,
various other sclerosing agents have been employed for the complete single-session
ablation of renal cysts, but no satisfactory long-term results have yet been documented
(12 16). There have been several encouraging reports on the use of low-energy
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Relectron-emitting radionuclides in the local radiation
treatment of small tumors and in radionuclide synovec-
tomy (17 25). To the best of our knowledge, however, so
far there have been no reports which described the
successful use of radionuclides for the ablation therapy of
renal cysts. The purpose of this study was to evaluate the
ability of a beta-emitting radionuclide (holmium-166-
chitosan complex) to act as a sclerosing agent for the
treatment of renal cysts.
MATERIALS AND METHODS
From March 2001 to February 2002, seventeen patients
underwent sclerosing therapy for renal cysts. There were
14 men and 3 women (mean age, 67 years; age range, 47
82 years). The indications for treatment were as follows: a
cyst larger than 5 cm in diameter (large cyst) that increased
in size during follow-up (n=10), a cyst with flank pain
(n=3), a cyst with hematuria (n=2), a large cyst with
impending rupture due to an adjacent abdominal aneurysm
(n=1) and the failure of previous ethanol sclerotherapy
(n=1). Informed consent was obtained from all of the
patients and all examinations were performed in
accordance with the recommendations of our institutional
review board.
Holmium solution (
166Ho (NO3)3 5H2O) was generated
at the Korea Atomic Energy Research Institute (Taejon,
Korea) and we used the holmium-166-chitosan complex in
this study. Chitosan is a polymer of 2-deoxy-2amino-D-
glucose with  -1, 4 bonds that is derived from the deacety-
lation of chitin. It was supplied by a Pharmaceutical
Development Laboratory (Dong Wha Pharm. Ind. Co.,
Ltd., Kyunggi-do, Korea).
A total of 20 renal cysts were included in this study.
They were evaluated by ultrasonography and, in each
case, the volume of the cyst was calculated using the
method described by Pedersen et al. (26), i.e.,
Volume =  (l w d) / 
[l; length, w; width, d; depth of the cyst]
Under ultrasonographic guidance, an 18 21 G puncture
needle was placed in the cyst, and as much as possible of
the cystic fluid was gently aspirated. Depending on the
volume of the cyst, 10 30 mCi (1 2 ml) of holmium-166-
chitosan complex was administered through the puncture
needle; 10 mCi for cysts < 100 ml, 20 mCi for cysts from
100 to 150 ml and 30 mCi for cysts > 150 ml. After the
procedure, gamma camera imaging was performed to
verify whether any leakage occurred.
Serial follow-up ultrasonography and a complete blood
count and urine analysis were performed for a period of
6 36 months: where possible, these tests were scheduled
at 1 2 month(s) and 6, 12 and 18 months. The volume of
the cysts before and after the sclerotherapy and the
percentage volume change were calculated, in order to
evaluate the response to therapy. The treatment effects
were classified as complete regression (invisible), nearly
complete regression (< 15 volume% of the initial volume),
partial regression (15 50 volume% of the initial volume),
and no regression (> 50 volume% of the initial volume).
RESULTS
The calculated volume of the cysts before sclerotherapy
ranged from 16 to 258 ml, with a mean volume of 90 ml.
Aspirated fluids from all cysts were clear transudates with
no microscopically detected presence of malignant or
atypical cells. Upon gamma camera examination, the
radioactivity was found to be localized at the site of
administration in all patients, without any distribution to
the other organs or tissues.
The mean follow-up period was 28 months (6 36
months). At the initial follow-up after 1 2 month(s), the
mean volume of the remaining cysts was 33% of the initial
volume. At the 6-month follow-up, the mean volume
decreased to 15% of the initial volume. At the 12-month
follow-up, the mean volume further decreased to 10% of
the initial volume. At the final follow-up, the mean
residual volume was 8% of the initial volume. Eighteen
cysts (90%) were completely (n=11, 55%) or nearly
completely (n=7, 35%) regressed (Figs. 1, 2). Partial
regression was obtained in 5% of cases (n=1) and there
was no regression in one patient (5%) (Table 1). An
organizing hematoma developed in one patient, and this
seems to have been the reason for the absence of regres-
sion of the cyst in this patient.
No patients complained of any significant pain during the
procedure. No significant complications were encountered
during or after the procedure, other than in the case of one
patient who showed a mild fever for three days without
leukocytosis, and in whom the fever subsided without
treatment. There were no remarkable findings on the
follow-up complete blood counts and urine analyses and
there were no further complaints about flank pain.
DISCUSSION
Management of symptomatic renal cysts can be
accomplished by several methods. Surgical resection is still
the treatment of choice for renal cysts. Recently, laparo-
scopic decortication or marsupialization of simple renal
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Fig. 1. A 57-year-old man with right flank discomfort.
A. Sonography of the left kidney demonstrated a giant simple cyst. The initial volume was 172 ml.
B, C. Under sonographic guidance, an 18 G puncture needle was placed in the cyst (B) and as much as possible of the cystic fluid was
gently aspirated. 30 mCi of holmium-166 chitosan complex was administered at the site of the placed puncture needle (C).
D. Gamma camera image (coronal anterior view) showed the focal accumulation of radioactivity without any evidence of leakage.
E. On the sonogram 1 month after the procedure, the cyst was found to have decreased to a volume of 47 ml.
F. The cyst disappeared at follow-up sonography 6 months after the procedure.
EF
AB
CDcysts was introduced to reduce the procedure related
morbidity (27 30). However, both modalities are
invasive, requiring general anesthesia with the accompany-
ing operative morbidity and complications that this brings.
Thus, they have been replaced by minimally invasive
approaches that are based on percutaneous needle aspira-
tion or sclerotherapy (9).
Aspiration of renal cysts under ultrasonographic or CT
guidance has previously been performed for diagnosis and
treatment, but renal cysts treated by simple aspiration
frequently recur because the secretory epithelial lining
remains. In such cases, the recurrence rate after 2 years
was reported to be as high as 80% (11). Many sclerosing
agents have been used to destroy the secretory epithelium
and so prevent cyst recurrence following aspiration.
Ethanol has generally been viewed as a safe and effective
sclerosing agent, and it has shown good initial results.
However, ethanol use is associated with various complica-
tions, including pain, fever and systemic reactions, such as
drunkenness and shock. In addition, its effectiveness is
reduced by dilution from the remaining cystic fluid and the
recurrence rate after a single-session of sclerotherapy has
been reported to be as high as 32% at the 2-year follow-up
(11).
Direct intratumoral injection of high-energy beta-
emitting radionuclides has been introduced as a potential
alternative to systemic targeted therapy for the local
control of solid tumors. Holium-166 attached to diverse
carriers has been used effectively not only in radionuclide
synovectomy (17, 18), but also in the treatment of solid
hepatic tumors (19 22) and for the treatment of skin
cancer (23, 24). Holmium-166 may also be appropriate for
the radionuclide sclerotherapy of renal cysts: it has a
relatively short half-life of 26.83 hours, a short penetration
range of 2.3mm, a high beta-energy (1.85 MeV) and a low
Percutaneous Sclerotherapy of Renal Cysts with a Beta-Emitting Radionuclide
Korean J Radiol 5(2), June 2004 131
Table 1. Summary of Therapeutic Responses
Response to Therapy % of Volume Change % of Cases
Complete regression invisible 55% (n=11)
Nearly complete regression < 15 volume %  35% (n=17)
of inital volume
Partial regression 15-50 volume % 15% (n=11)
No regression > 50 volume % 15% (n=11)
Fig. 2. A 76-year-old man with hematuria.
A. This patient underwent renal cyst 95% ethanol sclerother-
apy 2 years previously. However, a remnant cortical cyst
was noted at the lower pole of the left kidney on sonography,
with a calculated volume of 35 ml.
B. Follow-up sonography 2 months later showed a signifi-
cantly reduced cyst volume of 2 ml.
C. On follow-up sonography at 14 months, the cyst was
undetectable, indicating a complete regression.
C
ABgamma-energy (0.08 MeV). Furthermore, holmium-166 is
retained at the administration site where it forms a
chelated complex with chitosan (25). The emitted beta
particles ablate the lining epithelium of the cysts however,
unlike in the case of external beam irradiation in which the
much higher energy gamma radiation is used, only a
negligible dosage attains the perilesional structures and the
adjacent renal parenchyma is not damaged.
The holmium-166-chitosan complex has some positive
merits as a sclerosing agent. First, sclerotherapy performed
using this agent is painless. Second, the therapy can be
completed in a single session with just 1 2 ml of a scleros-
ing agent. Third, no significant procedure-related complica-
tions have been noted. Fourth, the procedure is very
simple, because there is no need to evacuate or irrigate the
treatment site after the agent’s instillation. Fifth, there is
little risk of leakage, because the holmium-166 chitosan
complex is transformed into a gelatinous substance under
neutral conditions. Furthermore, this beta-ray emitting
agent may allow for the effective treatment of mildly
complicated cysts.
One limitation of the present study was that regular
follow-up could not be performed for all patients.
However, the cysts showed a tendency towards gradual
obliteration and 90% of the cysts completely regressed at
the final follow up. Only one cyst showed no regression.
Although this patient was classified into a ‘no regression’
group, because of the development of the organizing
hematoma, no remnants of the cystic contents remained in
this case. Moreover, the mass-like hematoma had slowly
involuted on the serial follow-up (43 ml initially, 38 ml
immediate after treatment, and 30 ml at 30-month follow-
up ultrasound). So, even if we exclude the three cases in
which the follow-up period was limited to 6 months and
the one case of organizing hematoma formation, the
remainder of the patients showed satisfactory outcomes
with complete or near-complete regression. These
excellent results were probably due to the complete
denudation of the epithelial lining.
In our series, 90% of the cysts had a complete or near
complete regression at the final follow up after the single-
session sclerotherapy using the holmium-166 chitosan
complex. We believe the holmium-166 chitosan complex
to be a valuable new painless sclerosing agent, which can
be used for the treatment of renal cysts without significant
complications.
References
1. Nascimento AB, Mitchell DG, Zhang X-M, Kamishima T,
Parker L, Holland GA. Rapid MR imaging detection of renal
cysts: age-based standards. Radiology 2001;221:628-632
2. Terada N, Ichioka K, Matsuta Y, Okubo K, Yoshimura K, Arai
Y. The natural history of simple renal cysts. J Urol 2002;
167:21-23
3. Pal DK, Kundu AK, Das S. Simple renal cysts: and observation.
J Indian Med Assoc 1997;95:555-558
4. Rockson SG, Stone RA, Gunnells JC Jr. Solitary renal cyst with
segmental ischemia and hypertension. J Urol 1974;112:550-552
5. Churchill D, Kimoff R, Pinsky M, et al. Solitary intrarenal cyst:
correctable cause of hypertension. Urology 1975;6:485-488
6. Luscher TF, Wanner C, Siegenthanler W, Vetter W. Simple
renal cyst and hypertension: cause or coincidence? Clin Nephrol
1986;26:91-95
7. Choyke PL. Inherited cystic diseases of the kidney. Radiol Clin
North Am 1996;34:925-946
8. Evans AT, Coughlin JP. Urinary obstruction due to renal cysts. J
Urol 1970;103:277-280
9. Bean WJ. Renal cyst: treatment with alcohol. Radiology 1981;
138:329-331
10. Chung BH, Kim JH, Hong CH, Yang SC, Lee MS. Comparison
of single and multiple sessions of percutaneous sclerotherapy for
simple renal cyst. BJU International 2000;85:626-627
11. Hanna RM, Dahniya MH. Aspiration and sclerotherapy of
symptomatic simple renal cysts: value of two injections of
sclerosing agents. AJR Am J Roentgenol 1996;167:781-783
12. Brown B, Sharifi R, Lee M. Ethanolamine sclerotherapy. J Urol
1995;153:385-386
13. Ohkawa M, Tokunaga S, Orito M, et al. Percutaneous injection
sclerotherapy with minocycline hydrochloride for simple renal
cysts. Int Urol Nephrol 1993;25:37-43
14. Seo TS, Oh JH, Yoon Y, et al. Acetic acid as a sclerosing agent
for renal cysts: comparison with ethanol in follow-up results.
Cardiovasc Intervent Radiol 2000;23:177-181
15. Phelan M, Zajko A, Hrebinko RL. Preliminary results of
percutaneous treatment of renal cysts with povidone-iodine.
Urology 1999;53:816-827
16. Ohta S, Fujishiro Y, Fuse H. Polidocanol sclerotherapy for
simple renal cysts. Urologia Internationalis 1997;58:145-147
17. Song J, Suh CH, Park YB, et al. A phase I/IIa study on intra-
articular injection of holmium-166-chitosan complex for the
treatment of knee synovitis of rheumatoid arthritis. Eur J Nucl
Med 2001;28:489-497
18. Ofluoglu S, Schwameis E, Zehetgruber H, et al. Radiation
synovectomy with (166)Ho-ferric hydroxide: a first experience.
J Nucl Med 2002;43:1489-1494
19. Chung JI, Han GH, Lee JT, et al. Percutaneous intratumoral
injection of DW-166 HC in patients with hepatocellular
carcinoma: phase I and II study. Korean J Gastroenterol
1998;32:120-125
20. Lee JT, Kim EK, Won JY, et al. Experimental and clinical
studies on the intraarterial injection of holmium-166 chitosan
complex in the treatment of hepatocellular carcinoma. J Korean
Radiol Soc 2001;44:441-451
21. Nijsen F, Rook D, Brandt C, et al. Targeting of liver tumour in
rats by selective delivery of holmium-166 loaded microspheres:
a biodistribution study. Eur J Nucl Med 2001;28:743-749
22. Nijsen JF, Zonnenberg BA, Woittiez JR, et al. Holmium-166
poly lactic acid microspheres applicable for intra-arterial
radionuclide therapy of hepatic malignancies: effects of prepara-
tion and neutron activation techniques. Eur J Nucl Med 1999;
26:699-704
23. Lee JD, Yang WI, Lee MG, et al. Effective local control of
malignant melanoma by intratumoural injection of a beta-
Kim et al.
132 Korean J Radiol 5(2), June 2004Percutaneous Sclerotherapy of Renal Cysts with a Beta-Emitting Radionuclide
Korean J Radiol 5(2), June 2004 133
emitting radionuclide. Eur J Nucl Med Mol Imaging
2002;29:221-230
24. Lee JD, Park KK, Lee MG, et al. Radionuclide therapy of skin
cancers and Bowen’s disease using a specially designed skin
patch. J Nucl Med 1997;38:697-702
25. Suzuki YS, Momose Y, Higashi N, et al. Biodistribution and
kinetics of holmium-166-chitosan complex (DW-166HC) in rats
and mice. J Nucl Med 1998;39:2161-2166
26. Pedersen JF, Emamian SA, Nielsen MB. Simple renal cysts:
relation to age and arterial blood pressure. Br J Radiol 1993;66:
581-584
27. Dunn MD, Clayman RV. Laparoscopic management of renal
cystic disease. World J Urol 2000;18:272-277
28. Hoenig DM, McDougall EM, Shalhav AL, Elbahnasy AM,
Clayman RV. Laparoscopic management of renal cystic disease.
J Urol 1997;158:1345-1348
29. Rubenstein SC, Hulbert JC, Pharand D, Schuessler WW,
Vancaillie TG, Kavoussi LR. Laparoscopic ablation of sympto-
matic renal cysts. J Urol 1993;150:1103-1106
30. Jeng KS, Yang FS, Kao CR, Huang SH. Management of sympto-
matic polycystic liver disease: laparoscopy adjuvant with
alcohol sclerotherapy. J Gastroenterol Hepatol 1995;10:359-
362